LRRK2 and Parkinson disease: These findings were confirmed in another LRRK2 G2019S PD patient line (LRRK2-PD2), whereby an increase of GCase activity upon quetiapine treatment resulted in the reduction of oxidized DA (Supplemental Figure 4).